The article focuses on the challenges faced due to limited data and its effect on finding optimal balanced treatment for chronic myeloid leukemia (CML). It notes the risk of CML patients during pregnancy including the exposure of tyrosine kinase inhibitors (TKI), and the possibility of disease relapse due to discontinuation of TKI.